You just read:

Early Findings with Pembrolizumab, Merck's Investigational Anti-PD-1 Therapy, in Patients with Advanced Pleural Mesothelioma Presented at AACR Annual Meeting

News provided by

Merck

Apr 19, 2015, 12:45 ET